Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00049036 · FLOW

Participant flow

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma · Source last updated 2014-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
    id
    FG000
    title
    EPOCH + Concurrent Rituximab
  2. description
    Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
    id
    FG001
    title
    EPOCH Followed by Rituximab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        51
      2. group Id
        FG001
        num Subjects
        55
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        51
      2. group Id
        FG001
        num Subjects
        55
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
    id
    FG000
    title
    EPOCH + Concurrent Rituximab
  2. description
    Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
    id
    FG001
    title
    EPOCH Followed by Rituximab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        51
      2. group Id
        FG001
        num Subjects
        55
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        51
      2. group Id
        FG001
        num Subjects
        55
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice